Drug Profile
Research programme: RSV infections therapeutics - Arrow Therapeutics
Alternative Names: 1,4-benzodiazepines as RSV inhibitors - Arrow Therapeutics; A 62066; A-33903; A-58175; A-58568; A-58569; Follow-up RSV compounds - Arrow TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Arrow Therapeutics
- Class Benzodiazepines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in United Kingdom (PO)
- 02 Oct 2008 Preclinical development is ongoing in the United Kingdom (PO)
- 03 Nov 2006 Preclinical trials in Respiratory syncytial virus infections in United Kingdom (unspecified route)